{"filings":[{"id":1258718,"accession_number":"0001193125-26-281817","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-06-25T11:10:11+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.","Phase 3 trials in atopic dermatitis planned to initiate by mid-2027, subject to regulatory discussions.","BROADEN2 is a randomized, double-blind, placebo-controlled trial in ~200 patients ages 12-75 over 16 weeks.","KT-621 also in BREADTH Phase 2b asthma trial with data expected in late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1249437,"accession_number":"0001193125-26-281051","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-06-24T20:07:58+00:00","items":["5.07"],"status":"ready","headline":"Kymera annual meeting results: all Class III directors elected, say-on-pay approved, EY ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for 3-year terms.","Advisory vote on named executive officer compensation passed with 74.9M for, 2.5M against, 26.6K abstain.","Ratified Ernst & Young as independent auditor for FY2026 with 79.0M for, 38.1K against, 18.2K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918080,"accession_number":"0001193125-26-261698","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-06-08T20:05:07+00:00","items":["5.02"],"status":"ready","headline":"Kymera Therapeutics COO Jeremy Chadwick resigns effective June 5, 2026; will advise through Nov 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Jeremy Chadwick resigned for personal reasons, not due to any disagreement with company policies.","Chadwick will remain as an employee advisor until November 2026.","No replacement COO has been named by the company.","Chadwick communicated his intention to retire and submitted resignation on June 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95702,"accession_number":"0001193125-26-193957","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.","Collaboration revenue $34.4M (all from Gilead), up from $22.1M in Q1 2025.","Gilead exercised option to license KT-200 (oral CDK2 degrader), triggering a $45M milestone payment.","KT-621 Phase 2b BROADEN2 (AD) data expected mid-2027; BREADTH (asthma) data late 2027; FDA Fast Track for asthma.","KT-579 Phase 1 healthy volunteer trial ongoing; data expected in 2H26; KT-485/SAR447971 IND complete, clinical entry 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":34365000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108960,"accession_number":"0001193125-26-129170","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Kymera Therapeutics amends bylaws to designate federal courts for securities claims","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.","Federal district courts designated exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934.","Amendment effective immediately; company may consent to alternative forum in writing.","Change made in response to recent amendments to Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108959,"accession_number":"0001193125-26-073561","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.","TD Cowen will receive up to 3.0% commission on gross proceeds from sales under the agreement.","Kymera terminated its prior Open Market Sale Agreement with Jefferies LLC effective February 26, 2026.","Kymera filed a resale prospectus for up to 18,819,826 shares and 12,565,253 warrant shares held by certain stockholders.","The resale filing does not guarantee any sales and Kymera will not receive proceeds from resales by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108958,"accession_number":"0001193125-26-073386","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.","KT-621 (STAT6) Phase 2b in atopic dermatitis (enrollment ongoing) and asthma (dosing started); data expected mid- and late-2027.","KT-579 (IRF5) Phase 1 healthy volunteer trial dosed; data expected in 2H26.","Appointed Dr. Neil Graham as Chief Development Officer; he led dupilumab development at Regeneron.","FY2025 collaboration revenue $39.2M, R&D expense $316.6M, net loss $311.4M (vs. $223.9M in FY2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":39211000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108957,"accession_number":"0001193125-26-011104","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.","KT-621 Phase 2b BROADEN2 trial in AD enrolling, data expected by mid-2027; BREADTH Phase 2b asthma trial initiated, data late-2027.","KT-579 Phase 1 healthy volunteer trial expected to start 1Q26 with data in 2H26; IRF5 degrader for lupus, RA.","At least one new first-in-class oral immunology development candidate to advance towards IND in 2026.","Partnered programs: KT-485/SAR447971 (IRAK4) with Sanofi Phase 1 expected in 2026; CDK2 program with Gilead ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125410,"accession_number":"0001193125-25-314422","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kymera prices upsized $602M public offering; net ~$656M for pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.","Underwriters exercised option to purchase additional 1,050,000 shares in full.","Net proceeds estimated at ~$656.1M after discounts and expenses.","Cash runway extended into 2029; funds to advance degrader pipeline and working capital.","Offering expected to close December 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125409,"accession_number":"0001193125-25-310670","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.","Specific efficacy, safety, and biomarker outcomes not available from provided text.","Conference call hosted by CEO Nello Mainolfi and CMO Jared Gollob.","KT-621 is first-in-class oral STAT6 degrader targeting Th2-driven inflammation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125408,"accession_number":"0001193125-25-310572","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.","Mean EASI reduction of 63% and mean peak pruritus NRS reduction of 40% across all patients; rapid onset by Day 8.","Type 2 biomarker reductions: TARC down 74% in patients with baseline ≥1,600 pg/mL; Eotaxin-3 reductions numerically exceeded dupilumab at 52 weeks.","First known demonstration of IL-31 reduction and FeNO reduction in AD patients via IL-4/13 pathway blockade.","Well-tolerated with no SAEs, no treatment-related AEs, no conjunctivitis; Phase 2b BROADEN2 ongoing (data mid-2027) and BREADTH asthma trial starts 1Q26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125407,"accession_number":"0001193125-25-263540","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.","Cash $978.7M as of Sept 30; runway into H2 2028 beyond multiple pipeline milestones.","KT-621 Phase 1b AD trial (BroADen) enrollment complete; top-line data expected Dec 2025.","KT-621 Phase 2b AD trial (BROADEN2) initiated; asthma Phase 2b (BREADTH) on track for 1Q26.","KT-579 (IRF5) IND-enabling studies completed; Phase 1 planned for early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":36341000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142145,"accession_number":"0001193125-25-194481","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kymera Therapeutics appoints Brian Adams as Chief Legal Officer; Ellen Chiniara retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ellen Chiniara, Chief Legal Officer, retires effective Sept 3, 2025; departure not due to any disagreement with the company.","Brian Adams appointed Chief Legal Officer and Corporate Secretary, effective Sept 3, 2025.","Adams previously served as CLO of Relay Therapeutics and held senior legal roles at Keryx, Algeta, AVEO, and Genzyme.","Chiniara receives no severance; she will focus on board service and mentoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142144,"accession_number":"0000950170-25-106227","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.","Cash ~$1B as of July 31, 2025 (including $250M equity offering and Gilead upfront); runway into H2 2028.","KT-621 Phase 1 healthy volunteer: deep STAT6 degradation, safety undifferentiated from placebo; Phase 1b AD data expected 4Q25; Phase 2b AD/asthma start 4Q25/1Q26.","Gilead partnership for CDK2 molecular glue: up to $750M total payments including up to $85M upfront/option; Kymera leads research.","Sanofi to advance KT-485 (IRAK4) into Phase 1 in 2026; $20M preclinical milestone achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":33576000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160128,"accession_number":"0001193125-25-151393","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kymera prices $250.8M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.","Net proceeds estimated at $237.3M (or $272.7M if underwriters option for 855K shares exercised).","Proceeds to advance preclinical/clinical degrader programs and for working capital.","Existing cash plus offering proceeds expected to fund operations into mid 2028.","Company also entered registration rights agreement with Baker, Atlas, and BVF affiliates for up to 27.96M resale shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160127,"accession_number":"0001193125-25-151345","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kymera shareholders elect Albers and Baker as Class II directors at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey Albers elected with 55,765,189 votes for, 3,142,251 withheld.","Felix J. Baker elected with 51,745,887 votes for, 7,161,553 withheld.","Advisory say-on-pay resolution approved: 54,364,880 for, 4,531,413 against.","Ernst & Young ratified as independent auditor for FY2025 with 61,644,725 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160126,"accession_number":"0001193125-25-146135","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.","KT-485 showed improved potency, selectivity, and safety profile vs KT-474 in preclinical testing.","Kymera earned a $20M milestone in Q2 2025 for preclinical activities on KT-485.","Kymera eligible for up to $975M in milestones plus double-digit royalties; may opt-in to 50/50 U.S. profit share.","Sanofi exercised participation election right for IRAK4 target under collaboration agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160125,"accession_number":"0001193125-25-146134","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Up to $750M total payments including $85M upfront/option exercise payments.","Tiered royalties ranging from high-single-digit to mid-teens on net sales.","Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.","CDK2 degraders target breast cancer and other solid tumors.","Agreement announced June 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160124,"accession_number":"0001193125-25-132838","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.","Slide presentation furnished as Exhibit 99.1; specific safety, PK/PD, or efficacy data not provided in available text.","KT-621 targets immuno-inflammatory diseases; Phase 1 study in healthy volunteers completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160123,"accession_number":"0001193125-25-132760","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera reports positive Phase 1 data for oral STAT6 degrader KT-621; >90% STAT6 degradation at low doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.","MAD: complete STAT6 degradation in blood and skin at doses ≥50 mg; safety undifferentiated from placebo with no SAEs.","Th2 biomarkers: median TARC -37%, Eotaxin-3 -63% at Day 14, comparable or superior to dupilumab in healthy volunteers.","KT-621 well-tolerated: no TRAEs in >1 subject, no severe AEs, no discontinuations, no clinically relevant lab/ECG changes.","Next steps: Phase 1b AD data Q4 2025; Phase 2b AD start Q4 2025, asthma Q1 2026, enabling parallel Phase 3 readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160122,"accession_number":"0001193125-25-116443","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.","Cash $775M as of Mar 31, 2025; runway extended into H1 2028.","KT-621 (STAT6) Ph1 SAD/MAD healthy volunteer data due June 2025; BroADen Ph1b in AD started, data 4Q25.","New oral IRF5 degrader KT-579 unveiled; IND-enabling ongoing, Phase 1 expected early 2026.","Strategic decision to not advance KT-295 (TYK2) into clinic; focus on STAT6 and IRF5."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":22100000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178443,"accession_number":"0001193125-25-044151","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kymera grants PSUs to key employees with three clinical milestone vesting targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PSUs vest in three installments: 40% for first milestone, 40% for second, 20% for third.","No PSUs vest before first anniversary of grant date; total payout ranges 0-100% of target.","Grants approved March 3, 2025 under 2020 Stock Plan for named executive officers and management.","Target number of PSUs not disclosed; full award terms to be filed in Q1 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178442,"accession_number":"0001193125-25-037588","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.","Cash $851M as of Dec 31, 2024; runway into mid-2027.","KT-621 Phase 1 SAD/MAD data June 2025; Phase 1b AD starts 2Q25 with data 4Q25; Phase 2b AD/asthma 4Q25/1Q26.","KT-295 (TYK2) Phase 1 starts 2Q25 with data 4Q25; new first-in-class program announced May 2025.","Director Leigh Morgan not standing for reelection; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":47072000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178441,"accession_number":"0001193125-25-006124","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.","KT-621 Phase 1 healthy volunteer data expected Q2 2025; Phase 1b AD starts Q2 2025 with data Q4 2025.","KT-295 (TYK2) IND/Phase 1 start Q2 2025; data expected late 2025.","KT-474 (IRAK4) Phase 2b dose-ranging in HS and AD ongoing, completion expected 1H26 and mid-2026.","Novel oral immunology program (first-in-class) to be disclosed 1H2025; clinical testing expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195104,"accession_number":"0000950170-24-119245","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.","Initiated Phase 1 dosing for KT-621 (STAT6 degrader); Phase 1 data expected H1 2025.","Sanofi expands KT-474 (IRAK4) Phase 2 HS/AD trials to dose-ranging Phase 2b; primary completion mid-2026.","Selected KT-295 (TYK2 degrader) as development candidate; Phase 1 start in H1 2025.","Cash $911M as of Sep 30, 2024; runway into mid-2027; will only advance oncology with partner."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":39678000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211390,"accession_number":"0001193125-24-203755","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kymera prices $225M offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.","Net proceeds estimated at ~$246.5M after underwriting discounts and expenses.","Underwriters exercised 30-day option to purchase additional 828,220 shares in full.","Proceeds to advance preclinical and clinical degrader programs and for working capital.","Existing cash plus offering proceeds expected to fund operations into mid 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211389,"accession_number":"0000950170-24-092272","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.","Cash & equivalents $702M as of June 30, 2024; projected runway into first half 2027.","Sanofi plans to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after interim safety/efficacy review.","STAT6 degrader KT-621 Phase 1 on track for H2 2024; TYK2 degrader KT-294 Phase 1 in H1 2025.","KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment completion expected H2 2024 with data presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":35937000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211388,"accession_number":"0001193125-24-176312","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sanofi expands KT-474 Phase 2 trials in HS and AD after positive interim data review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi to expand ongoing Phase 2 trials for KT-474 in hidradenitis suppurativa and atopic dermatitis.","Expansion follows interim safety and efficacy review by an Independent Data Review Committee.","Move intended to accelerate timelines and progress toward pivotal registrational studies.","Kymera CEO Nello Mainolfi cites potential to address large unmet needs with high market potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230015,"accession_number":"0001193125-24-164550","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director Horobin resigns; shareholders approve plan amendment to include pre-funded warrants in evergreen","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.","Jeffrey Albers appointed to Audit Committee; committee now consists of Ridloff, Esposito, Albers.","Shareholders approved Amendment No. 1 to 2020 Stock Option Plan: 'Outstanding Shares' includes pre-funded warrants for annual evergreen increase.","Shareholders elected Class I directors (Esposito, Hrustanovic, Sandor) and ratified Ernst & Young as independent auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230014,"accession_number":"0000950170-24-051566","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.","Cash, cash equivalents and investments $745M as of March 31, 2024.","Cash runway extended into first half of 2027 following $301M equity offering.","KT-474 IRAK4 degrader Phase 2 trials in HS and AD ongoing; topline data H1 2025.","KT-621 STAT6 degrader Phase 1 start H2 2024; KT-294 TYK2 degrader Phase 1 start H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":10287000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230013,"accession_number":"0001193125-24-082641","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kymera appoints Felix J. Baker as director and Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Felix J. Baker appointed to Board as Class II director effective March 28, 2024; also named Lead Independent Director.","Dr. Baker is managing member of Baker Bros. Advisors LP, which is affiliated with shareholders holding >5% of stock.","Baker affiliates purchased 4,950,495 pre-funded warrants at $25.2499 each in January 2024; Dr. Baker deemed beneficial owner.","Compensation: option to purchase 32,000 shares at closing price on March 28, vesting over 3 years; annual retainer $60,000 as Lead Independent Director.","Board determined Dr. Baker independent under Nasdaq standards; committee assignments pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248456,"accession_number":"0000950170-24-018413","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.","Cash and investments $745M as of Jan 9, 2024, including $301M from equity offering; runway into H1 2027.","KT-474 Phase 2 trials in HS and AD started; topline data expected H1 2025; $55M milestone from Sanofi.","KT-621 STAT6 degrader Phase 1 expected H2 2024; KT-294 TYK2 Phase 1 expected H1 2025; data in 2025.","Additional Phase 1 data for KT-333 (STAT3) and KT-253 (MDM2) expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":78592000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248455,"accession_number":"0001193125-24-003373","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Kymera prices $275M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 2.25M shares at $25.25 and 8.64M pre-funded warrants at $25.2499; gross proceeds ~$275M.","Underwriters' option for additional 1.63M shares exercised in full; net proceeds estimated ~$301.1M.","Preliminary cash, cash equivalents and marketable securities of ~$436M as of Dec 31, 2023, excluding $15M Sanofi milestone.","Cash runway expected into first half of 2027 based on current plans and offering proceeds.","Offering led by Morgan Stanley, J.P. Morgan, and TD Cowen; close expected Jan 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248454,"accession_number":"0001193125-24-002424","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kymera holds immunology R&D day; discloses new targets and clinical timelines","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held virtual immunology R&D day on Jan 4, 2024, highlighting emerging pipeline.","New target disclosures and supporting preclinical data presented.","Clinical study initiation timing provided for immunology programs.","No financial data or earnings guidance included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248453,"accession_number":"0001193125-24-001884","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera unveils STAT6 degrader KT-621 (Phase 1 in H2 2024) and TYK2 degrader KT-294 (Phase 1 in H1 2025)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.","KT-294 (TYK2 degrader) planned to enter Phase 1 in H1 2025; potential to recapitulate TYK2 loss-of-function biology.","KT-474 (IRAK4 degrader) Phase 2 enrollment in HS and AD expected to complete Q4 2024; topline data H1 2025.","Both KT-621 and KT-294 are wholly-owned, once-daily oral degraders targeting validated autoimmune pathways.","Company holds virtual R&D Day on Jan 4, 2024 to present immunology strategy and new preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265960,"accession_number":"0001193125-23-268944","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["21 patients enrolled through dose level 5; 12 evaluable for disease assessment.","One partial response in cutaneous T-cell lymphoma (CTCL) at DL2; stable disease in 3 solid tumor patients (DL3/4).","No dose-limiting toxicities or serious adverse events; most AEs Grade 1/2 (constipation, fatigue, nausea, anemia).","Dose-dependent, sustained STAT3 degradation in PBMCs at DL3+ at levels linked to preclinical anti-tumor activity.","Updated data to be presented at ASH 2023 on December 10."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265959,"accession_number":"0001193125-23-268815","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.","First patient dosed in KT-474 (IRAK4) Phase 2 HS trial triggered $40M milestone from Sanofi; Phase 2 AD dosing expected Q4 2023.","KT-333 (STAT3) Phase 1 shows partial response in CTCL patient; Fast Track granted for CTCL/PTCL.","KT-253 (MDM2) achieved proof-of-mechanism; confirmed partial response in Merkel cell carcinoma patient.","KT-413 (IRAKIMiD) development discontinued; cash $435M provides runway into H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":30707000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283178,"accession_number":"0000950170-23-037578","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.","Cash & equivalents $472M as of June 30, 2023; cash runway into second half of 2025.","Partner Sanofi plans Phase 2 trials for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in Q4 2023.","Phase 1 data for KT-253 (MDM2), KT-333 (STAT3), KT-413 (IRAKIMiD) expected later in 2023.","Appointed Jeremy Chadwick as COO and Justine Koenigsberg as VP, Head of IR."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":25979000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302580,"accession_number":"0001193125-23-168977","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kymera Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for three-year terms.","Advisory vote on named executive officer compensation passed with 42.7M for, 1.5M against, 5K abstain.","Ratified Ernst & Young as independent auditor for FY2023 with 46.6M for, 3.2K against.","Broker non-votes: 2.46M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302579,"accession_number":"0001193125-23-150555","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kymera appoints Jeremy Chadwick as COO; base salary $480K, equity grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Chadwick, Ph.D., appointed COO effective May 22, 2023; previously SVP at Takeda.","Chadwick receives $480,000 annual base salary, target bonus 40% of base, plus benefits.","Chadwick granted option for 200,000 shares (4-year vest) and RSUs for 33,333 shares (annual vest)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302578,"accession_number":"0000950170-23-017458","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports Q1 net loss of $40.9M, cash $516M; initiates MDM2 degrader trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.9M vs $36.7M Q1 2022; R&D expenses $42.2M (up from $35.9M).","Cash and investments $516M as of March 31, 2023; runway into H2 2025.","Phase 1 trial of MDM2 degrader KT-253 initiated in relapsed/refractory myeloid malignancies and solid tumors.","KT-474 (IRAK4 degrader) Phase 2 planned in hidradenitis suppurativa for 2023; Phase 1 data at EADV May 18.","KT-333 and KT-413 Phase 1 updates at ICML in June; anti-tumor activity data expected later in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":9466000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322240,"accession_number":"0001193125-23-067797","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Kymera reports limited SVB exposure of $2.2M cash and $4.5M letter of credit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 10, 2023, Kymera holds $2.2M cash at Silicon Valley Bank (SVB) and $4.5M restricted cash letter of credit.","Total cash and equivalents reported at $560M as of Dec 31, 2022; SVB exposure represents <1% of cash.","Company does not anticipate any material impact on operations or liquidity from SVB closure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322239,"accession_number":"0001193125-23-051009","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kymera Therapeutics CBO Elaine Caughey to depart April 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Business Officer Elaine Caughey departing for personal family reasons.","Departure effective as of April 10, 2023.","No replacement or interim appointment announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322238,"accession_number":"0000950170-23-003930","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.","Collaboration revenue Q4 $16.1M, full year $46.8M; R&D expenses $43.1M Q4, $164.2M full year.","Sanofi to initiate Phase 2 trial of KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in 2023.","Phase 1 trials for KT-333 (STAT3) and KT-413 (IRAKIMiD) ongoing; clinical activity data expected in 2023.","KT-253 (MDM2) IND cleared; Phase 1 trial to start early 2023 in solid tumors and hematological malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":46826000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322237,"accession_number":"0001193125-23-005171","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.","KT-474 (IRAK4 degrader) Phase 2 trials in HS and AD to initiate in 2023 in collaboration with Sanofi.","KT-333 (STAT3) Phase 1 dose escalation ongoing; 66% mean STAT3 degradation in PBMC at first dose level.","KT-413 (IRAKIMiD) Phase 1 completed two dose levels; dose-dependent degradation of IRAK4, Ikaros, Aiolos; no DLTs.","KT-253 (MDM2) IND cleared; Phase 1a to start Q1 2023 in solid tumors and hematological malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340289,"accession_number":"0001193125-22-304456","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.","Also discussed updates on the company's oncology pipeline programs.","Full presentation furnished as Exhibit 99.1; no specific numerical results disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340288,"accession_number":"0001193125-22-304330","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kymera reports positive KT-474 Phase 1 data; Sanofi advances to Phase 2; oncology programs show target knockdown","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.","Sanofi committed to Phase 2 trials for KT-474 in HS and AD, with first study starting in 2023.","KT-413 (IRAKIMiD) showed up to 100% Ikaros/Aiolos knockdown and 40% IRAK4 knockdown at dose level 2; no DLTs.","KT-333 (STAT3) showed mean 66% STAT3 degradation (up to 86%) in PBMC at dose level 1; dose level 2 enrolling.","FDA cleared IND for KT-253 (MDM2 degrader); Phase 1 planned for early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340287,"accession_number":"0001193125-22-276377","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Kymera Q3 2022 net loss $43M, cash $596M; board adds Sandor as Nicholson resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2022 net loss $43.0M ($0.81/sh) vs $28.6M in Q3 2021; collaboration revenue $9.6M vs $20.3M.","Cash, equivalents & investments $595.6M as of Sep 30, 2022; includes $150M Aug 2022 private placement.","KT-474 (IRAK4 degrader) patient cohort dosing complete; data to Sanofi in Q4, clinical update Dec 14, 2022.","Director Don Nicholson resigned Nov 3, 2022 (no disagreement); Victor Sandor appointed to Board same day.","KT-333 (STAT3 degrader) granted second orphan drug designation (CTCL); KT-253 IND on track for Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340286,"accession_number":"0001193125-22-262193","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.","Will hold investor webcast on December 14, 2022 to present clinical data from KT-474 and oncology pipeline.","KT-333 (STAT3 degrader) and KT-413 (IRAKIMiD) continuing Phase 1 dose escalation.","KT-253 (MDM2 degrader) has completed IND enabling studies; expects to file IND by year-end 2022.","Collaboration with Sanofi for IRAK4 degrader development outside oncology/immune-oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357560,"accession_number":"0001193125-22-224656","cik":1815442,"company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Kymera raises $150M PIPE with 2.77M shares at $26 and 3M pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 2,769,228 common shares at $26.00 and 3,000,000 pre-funded warrants at $25.9999.","Gross proceeds of ~$150M expected; closing on August 22, 2022 subject to customary conditions.","Proceeds to fund working capital, R&D, and general corporate purposes.","Post-closing cash, equivalents, and investments expected to exceed $600M as of August 31, 2022.","Offering led by a US healthcare fund and BVF; includes Avoro, EcoR1, Redmile, Rock Springs, T. Rowe Price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640654477.865727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-19T23:59:59+00:00|357560"}